CUAJ E. Enfortumab Vedotin (EV) and Pembrolizumab (Pembro) Combination Treatment for Patients with Urological Cancers – Adverse Events (AEs): Management Tool Kit. CUAJ [Internet]. 2026 May 26 [cited 2026 May 31];15(1X). Available from: https://cuaj.ca/index.php/journal/article/view/9883